Sleven, it would not "invalidate every generic label" automatically, but it could cause some or all of them to voluntarily withdraw their use, OR, Amarin would need to sue them each individually.
It likely depends on the specific outcome of the trial, and what the language and judgement/damages are.
If the judgement is essentially "fix your marketing language", then it's still open season for generics. If the judgement is far more harsh, then the other generics would likely voluntarily withdraw, as none of them have a huge financial incentive to continue selling Icosapent Ethyl.
Let's also not forget that Hikma is still actively defending the suit, which means they still have a belief that they could win. We are all talking as if an Amarin win is fait accompli.
Market Data 
Markets 
AI
